Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.

ABSTRACT:

Purpose

To assess the duration, incidence, reversibility, and severity of adverse events (AEs) in patients with thyroid eye disease (TED) treated with teprotumumab.

Design

Multicenter, retrospective, observational cohort study.

Participants

Patients with TED of all stages and activity levels treated with at least 4 infusions of teprotumumab.

Methods

Patients were treated with teprotumumab between February 2020 and October 2022 at 6 tertiary centers. Adverse event metrics were recorded at each visit.

Main outcome measures

The primary outcomes measure was AE incidence and onset. Secondary outcome measures included AE severity, AE reversibility, AE duration, proptosis response, clinical activity score (CAS) reduction, and Gorman diplopia score improvement.<

SUBMITTER: Shah SA 

PROVIDER: S-EPMC10960718 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature